Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-05-09
1998-12-15
Grumbling, Matthew V.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514250, 544344, 544353, 544356, A61K 3154, A61K 31535
Patent
active
058497420
ABSTRACT:
The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction and particularly KDR/FLK-1 receptor signal transduction in order to regulate and/or modulate vasculogenesis and angiogenesis. The invention is based, in part, on the demonstration that KDR/FLK-1 tyrosine kinase receptor expression is associated with endothelial cells and the identification of vascular endothelial growth factor (VEGF) as the high affinity ligand of FLK-1. These results indicate a major role for KDR/FLX-1 in the signaling system during vasculogenesis and angiogenesis. Engineering of host cells that express FLK-1 and the uses of expressed FLK-1 to evaluate and screen for drugs and analogs of VEGF involved in FLK-1 modulation by either agonist or antagonist activities is also described.
The invention also relates to the use of the disclosed compounds in the treatment of disorders, including cancer, diabetes, hemangioma and Kaposi's sarcoma, which are related to vasculogenesis and angiogenesis.
REFERENCES:
patent: 3435064 (1969-03-01), Schipper et al.
patent: 3582315 (1971-06-01), Soper
patent: 3647793 (1972-03-01), Soper
patent: 4001017 (1977-01-01), Baumann et al.
patent: 4358307 (1982-11-01), Serban et al.
patent: 4772613 (1988-09-01), Parson et al.
patent: 4966849 (1990-10-01), Vallee et al.
patent: 5185438 (1993-02-01), Lemisschka
patent: 5217999 (1993-06-01), Levitzki et al.
patent: 5281619 (1994-01-01), Dell et al.
patent: 5302606 (1994-04-01), Spada et al.
patent: 5330992 (1994-07-01), Eissenstat et al.
patent: 5480883 (1996-01-01), Spada et al.
Saeed, Ali A.H., 1986, "Spectral Properties and Activities of Some New Potial Antileukemia Agents and Related Compounds," Canadian Journal of Spectroscopy, 31(2):40-43.
Saeed, Can. J. Spectroc. (1986), 31(2), 40-3, Feb. 1986.
Saeed, J. Heterocycl. Chem. (1983), 20(6), 1739-40, Feb. 1983.
Zamet et al., J. Chem. Soc., Perkins Transactions 1 (1974) (14), 1687-91, Mar. 1974.
Taylor, J. Org. Chem. (1980), 45(12), 2512-15, Apr. 1980.
Choudhury, Perkins Transactions 1974(1), pp. 129-132 (1974).
Gazit et al., 1993, "Tyrphostins. 3. Structure-Activity Relationship Studies of .alpha.-Substituted Benzylidenemalononitrile 5-S-Aryltyrphostins", J. Med. Chem. 36:3556-3564.
Kane et al., 1981, Heterocycles 16:1449-1452. Derivatives and Pharmaceutically Acceptable Salts Thereof, as well as Pharmaceutical Compositions Comprising Such as ACtive Ingredient", Chem. Abstr. vol. 117, Abstr. No. 212519.
Merlin et al., 1985, "Resonance Raman Study of Phenylhydrazonopropanedinitriles", Can. J. Chem. 63:1840-1844.
Miyoshi, H. et al., 1988, "Quantitative Analyses of the Uncoupling Activity of Substituted Phenols with Mitochondria from Flight Muscles of Houseflies", Biochim. Biophys. Acta 935:312-321.
Ohmichi et al., 1993, "The Tyrokinase Kinase Inhibitor Tyrphostin Blocks the Cellular Actions of Nerve Growth Factor", Biochem. 32:4650-4658.
Stout, D. et al., 1993, "Synthesis and Antiarrhythmic and Parasympatholytic Properties of Substituted Phenols 1. Heteroarylamine Derivatives", J. Med. Chem. 26:808-813.
Vogel, M. et al., 1987, "Synthese von 4-Substituierten 329, Heft 1:101-107.
App Harald
Gazit Aviv
Levitzki Alexander
McMahon Gerald M.
Tang Peng Cho
Grumbling Matthew V.
Sugen Inc.
Yissum Research Development Co. of The Hebrew Universuty of Jeru
LandOfFree
Compounds for the treament of disorders related to vasculogenesi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds for the treament of disorders related to vasculogenesi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for the treament of disorders related to vasculogenesi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1458178